Antifungal Drug Allergy: Infusion Reactions, Azole Rashes & Treatment

In the vast majority of cases, no. Amphotericin B deoxycholate infusion reactions — fever, chills, rigors, hypotension — affect up to 71% of patients and are driven by direct mast cell activation and pro-inflammatory cytokine release (TNF-alpha, IL-1, IL-6). This is a non-IgE pseudoallergic phenomenon, not true allergy. Serum tryptase measured during the reaction is typically normal, which helps distinguish it from IgE-mediated anaphylaxis. True IgE-confirmed amphotericin B anaphylaxis is extraordinarily rare, with only about 9 published cases. Most patients can continue amphotericin B therapy with a standard premedication protocol.

Potentially, yes. Cross-reactivity between azoles is documented but incomplete — the shared imidazole or triazole ring creates some structural overlap, but many patients who react to one azole tolerate another. The AAAAI 2022 Drug Allergy Practice Parameter recommends drug provocation testing as the gold standard for confirming tolerance to an alternative azole. Isavuconazole, the newest triazole approved in 2015, has better tolerability and a lower QT prolongation signal than voriconazole. Your allergist and infectious disease specialist can coordinate provocation testing to identify a safe alternative.

Voriconazole phototoxicity is a non-immunologic adverse reaction where the drug absorbs ultraviolet A (UVA) light and generates reactive oxygen species that damage skin cells. It occurs in approximately 2% of patients initially but increases with prolonged use. This is direct photochemical damage, not an allergic reaction — no prior sensitization is required. The clinical significance extends beyond sunburn: in solid organ transplant patients, chronic voriconazole phototoxicity is associated with a relative risk of 1.86 for squamous cell carcinoma. Strict sun protection and dermatologic monitoring are mandatory during therapy.

Terbinafine DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) typically presents 2 to 8 weeks after starting therapy. Symptoms include widespread skin rash (often starting on the face with edema), high fever, lymphadenopathy, elevated liver enzymes (hepatitis), and blood eosinophilia. Facial swelling is a characteristic feature. DRESS is a serious Type IVb immune reaction with potential organ damage, particularly to the liver. If you develop any combination of rash, fever, and feeling unwell several weeks after starting terbinafine, stop the medication and seek medical evaluation immediately.

No. Terbinafine-associated taste disturbance (dysgeusia or ageusia) affects approximately 2.8% of users and is a pharmacologic side effect, not an allergic reaction. The mechanism is not fully understood but may involve direct effects on taste receptor cells. Taste changes can persist for weeks to months after stopping the drug, which distinguishes this from allergic reactions that resolve more quickly after drug withdrawal. While distressing, this side effect does not indicate that future terbinafine use would cause a dangerous allergic reaction.

Echinocandin infusion reactions (affecting about 3% of patients) are typically mild to moderate and manifest as facial flushing, warmth, and sometimes mild hypotension. These are histamine-mediated reactions triggered by direct mast cell activation rather than IgE antibodies. Slowing the infusion rate is usually sufficient to manage symptoms. True IgE-mediated anaphylaxis to echinocandins is rare. Cross-reactivity between caspofungin, micafungin, and anidulafungin has been suggested by case reports, so switching between class members after an immediate hypersensitivity reaction should be approached with caution.

Yes. Topical azoles including clotrimazole, miconazole, and ketoconazole are well-documented causes of Type IV allergic contact dermatitis. The reaction presents as worsening redness, itching, and sometimes blistering at the application site — which patients and clinicians may initially misinterpret as treatment failure or worsening fungal infection. Cross-reactivity between topical azoles is high due to shared chemical structures. Patch testing by a dermatologist or allergist with the suspected agent confirms the diagnosis and guides selection of a safe alternative. Nystatin, a polyene structurally unrelated to azoles, is the standard topical alternative for azole-contact-allergic patients.

Antifungal allergy is an immune-mediated response — the body's immune system produces T cells or IgE antibodies against the drug or its metabolites — and presents as rash, urticaria, DRESS, or anaphylaxis. Antifungal toxicity is a dose-dependent pharmacologic effect unrelated to immune activation. Examples include ketoconazole hepatotoxicity (which led to its 2013 FDA black box warning and restriction from systemic use), amphotericin B nephrotoxicity, and terbinafine-associated liver injury at higher doses. Voriconazole periostitis from fluoride metabolite accumulation is toxicity, not allergy. The distinction guides management: toxicity usually responds to dose reduction or drug discontinuation, while true allergy may require complete avoidance or formal desensitization.